All In Biotech

Drug Trial Radar · NCT04045405

Clinical Study to Assess Safety, PK and PD Parameters of CDR132L

Phase I, Randomized, Double-blind, Placebo-controlled Study to Assess Safety, PK and PD Parameters of CDR132L in Patients With Stable Heart Failure of Ischemic Origin (NYHA 1- 3)

Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Jun 21, 2019

Primary completion

Jan 31, 2020

Study completion Jun 26, 2020

Sponsor

Lead sponsor
Cardior Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Aug 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, randomized, double-blind, placebo-controlled study to assess safety, pharmacokinetics and pharmacodynamic parameters of CDR132L in patients with stable heart failure of ischemic origin (NYHA 1-3).

Conditions

  • Heart Failure

Interventions

  • CDR132LDrug

    i.v. administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events [safety and tolerability]Time frame: 4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Richmond Pharmacology Ltd., 1A Newcomen Street, London Bridge

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.